Neuro-oncology
Literature Review
Pembrolizumab and Nivolumab May Cause Neurologic Events
Approximately 3% of patients developed adverse neurologic events within 12 months of receiving nivolumab or pembrolizumab, according to the...
From the Journals
Pembrolizumab, nivolumab linked to 3% rate of neurologic events
Ten of 347 patients (2.9%) receiving nivolumab or pembrolizumab developed subacute neurologic immune-related adverse events, typically...
Feature
Glioblastoma: Prognosis is poor, but new therapies are emerging
Intensive, up-front treatment may help elderly patients with glioblastoma the most.
Conference Coverage
Atezolizumab improves OS in NSCLC with brain metastases
GENEVA – Immune checkpoint inhibitors may improve survival in patients with non–small cell lung cancer (NSCLC) and brain metastases compared with...
Conference Coverage
Neuropathic pain puts cancer survivors out of work
Chronic neuropathic pain is a barrier to employment for many cancer survivors.
Conference Coverage
Detecting Autoimmune Neural Antibodies Is Key to Preventing Misdiagnosis
LAS VEGAS—Advances in autoimmune neurology, a rapidly evolving field, have the potential to prevent misdiagnosis of many disorders, from multiple...
Article
Is physician-assisted suicide compatible with the Hippocratic Oath?
Do we stand by our Hippocratic Oath when providing physician-assisted suicide?Physician-assisted suicide (PAS) is a form of euthanasia in which a...
Conference Coverage
Less cognitive decline with stereotactic radiosurgery after brain metastases resection
Key clinical point: Stereotactic radiosurgery following brain metastases resection was associated with similar survival but less toxicity than was...
Conference Coverage
Heat shock protein peptide vaccine appears safe, effective for glioblastoma patients
Key clinical point: A heat shock protein peptide vaccine appears safe and effective for patients with glioblastoma in an early stage trial. Major...
Conference Coverage
IL-2 adds only toxicity to neuroblastoma antibody tx
Key clinical point: IL-2 adds no benefit, only toxicity, to neuroblastoma antibody therapy. Major finding: Only 61% of treatment cycles were...
News
Early results positive for treating high-grade gliomas with virus-based therapy
Key clinical point: A phase I trial indicates that Toca 511 is safe and shows activity in treating patients with high-grade or recurrent...